Our Products

VPI-Benztropine

VPI-Benztropine is a synthetic compound resulting from the combination of the active portions of atropine and diphenhydramine. Benztropine possesses both anticholinergic and antihistaminic effects, although only the former have been established as therapeutically significant in the management of parkinsonism. Benztropine antagonizes the effect of acetylcholine. This decreases the imbalance between the neurotransmitters acetylcholine and dopamine, which may improve the symptoms of early Parkinson's disease.

VPI-Benztropine is recommended for all etiologic groups of parkinsonism - arteriosclerotic, postencephalitic, idiopathic and drug-induced. It can be effective at any stage of the disease, even when a patient has become bedridden. Often it is helpful in patients who have become unresponsive to other agents.

Proper Name	Benztropine Mesylate Injection, USP
Brand Reference	CogentinTM injectable
DIN	02486822
UPC	6 28804 00014 1
Strength	2 mg/2 mL
Dosage Form	Solution
Format	10 x 2 mL
Therapeutic Class	Antiparkinsonian Agent
Product Monograph
Product Code	VBEN100

VPI-Ethacrynate Sodium

VPI-Ethacrynate Sodium injection belongs to a group of medicines called loop diuretics. Ethacrynate Sodium is administered to treat fluid retention (edema) and swelling that is caused by congestive heart failure, acute pulmonary oedema, renal oedema, hepatic cirrhosis with ascites or other medical conditions.

Proper Name	Ethacrynate Sodium for injection, USP
Brand Reference	Sodium Edecrin®
DIN	02462362
UPC	6 28804 00011 0
Strength	50 mg
Dosage Form	Powder for Solution
Format	1
Therapeutic Class	Saluretic – Diuretic Agent
Product Monograph
Product Code	CVETH100